Alnylam Completes Enrollment of Phase II Clinical Trial and Initiates Open ... DailyFinance FAP patients have a life expectancy of five to 15 years from symptom onset, and the only treatment options for early stage disease are liver transplantation and tafamidis (approved in Europe). The mean survival for FAC patients is approximately 2.5 ... |
